Pfizer Inc. (PFE)

28,91 -1,56 (-5,12%) Börsenschluss: 04:00PM EST

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 83.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Albert Bourla D.V.M., Ph.D.	Chairman of the Board & CEO	11,72M	N/A	1962
Mr. David M. Denton	Chief Financial Officer & Executive VP	18,19M	N/A	1965
Dr. Mikael Dolsten M.D., Ph.D.	Chief Scientific Officer and President of Research & Development	5,82M	N/A	1958
Ms. Angela Hwang	Chief Commercial Officer & President of Global Biopharmaceuticals Business	4,89M	7,7M	1966
Ms. Jennifer B. Damico	Senior VP, Controller & Principal Accounting Officer	N/A	N/A	1968
Ms. Lidia L. Fonseca	Executive VP and Chief Digital & Technology Officer	N/A	N/A	1969
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	N/A	N/A	N/A
Mr. Douglas M. Lankler	Executive VP & General Counsel	3,78M	1,85M	1966
Mr. Rady A. Johnson	Executive VP and Chief Compliance, Quality & Risk Officer	N/A	N/A	1962
Mr. Andreas J. Panayiotou	Global Chief Marketing Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate Governance

Pfizer Inc.s ISS Governance QualityScore, Stand 1. Dezember 2023, lautet 5. Die grundlegenden Scores sind Audit: 10, Vorstand: 5, Shareholderrechte: 1, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.